CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study
Go back to CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study| Clinuvel Pharmaceuticals Ltd Sponsored ADR (AMEX: CLVLY) | Delayed: 7.30 -0.05 (0.68%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.35 | 52 Week High | $6.92 | |||
| Open | $7.25 | 52 Week Low | $1.79 | |||
| Day High | $7.36 | P/E | N/A | |||
| Day Low | $7.20 | EPS | $0.00 | |||
| Volume | 3,100 | |||||
| PC Universe, Inc. New (AMEX: CUV) | Delayed: 0.15 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.15 | 52 Week High | $0.15 | |||
| Open | $0.15 | 52 Week Low | $0.15 | |||
| Day High | $0.15 | P/E | N/A | |||
| Day Low | $0.15 | EPS | $0.00 | |||
| Volume | 0 | |||||
